Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Next Previous
Trial Profile

Phase 1/2 Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary) ; Axicabtagene ciloleucel; Brexucabtagene autoleucel; Cyclophosphamide; Fludarabine
  • Indications Cytokine release syndrome; Neurotoxicity syndrome
  • Focus Adverse reactions

Most Recent Events

  • 12 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 07 May 2024 Planned End Date changed from 30 Nov 2026 to 30 Oct 2027.
  • 07 May 2024 Planned primary completion date changed from 30 Nov 2026 to 30 Oct 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top